Compare NAZ & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAZ | SLGL |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.0M | 159.7M |
| IPO Year | N/A | 2018 |
| Metric | NAZ | SLGL |
|---|---|---|
| Price | $12.04 | $70.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 18.3K | ★ 27.2K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $9.22 | $4.02 |
| 52 Week High | $11.37 | $76.80 |
| Indicator | NAZ | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 73.05 |
| Support Level | $11.95 | $62.23 |
| Resistance Level | $12.08 | $67.78 |
| Average True Range (ATR) | 0.07 | 6.33 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 66.67 | 96.81 |
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.